Provided by Tiger Trade Technology Pte. Ltd.

Iovance Biotherapeutics, Inc.

13.33
+0.41503.21%
Volume:7.79M
Turnover:101.10M
Market Cap:6.04B
PE:-18.88
High:13.35
Open:12.65
Low:12.62
Close:12.92
52wk High:15.30
52wk Low:1.76
Shares:452.97M
Float Shares:394.00M
Volume Ratio:0.76
T/O Rate:1.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7058
EPS(LYR):-1.0941
ROE:-40.36%
ROA:-20.31%
PB:8.20
PE(LYR):-12.18

Loading ...

Iovance Q2 2026 Earnings: Amtagvi Drives 66% Revenue Growth and a Narrower Loss

TradingKey
·
Aug 06

Earnings Flash (IOVA) Iovance Biotherapeutics Posts Q2 Loss $0.11 a Share, vs. FactSet Est of $0.13 Loss

MT Newswires Live
·
Aug 06

Iovance Biotherapeutics Shares Rise 13.4% Premarket After Q2 Revenue Beat

THOMSON REUTERS
·
Aug 06

Iovance Q2 Operating Loss Narrows to $51.91 Million; Revenue Rises 66% Year over Year to $99.31 Million

Reuters
·
Aug 06

Iovance Biotherapeutics Q2 EPS $(0.11) Beats $(0.14) Estimate, Sales $99.313M Beat $87.832M Estimate

Benzinga Earnings
·
Aug 06

Iovance Biotherapeutics - Reviewing Fy2026 Revenue Guidance of $350 Mln to $370 Mln

THOMSON REUTERS
·
Aug 06

Iovance Biotherapeutics Q2 Revenue USD 99.313 Million

THOMSON REUTERS
·
Aug 06

Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99m, Business Achievements, and Corporate Updates

THOMSON REUTERS
·
Aug 06

Iovance Biotherapeutics (IOVA) Is Down 18.4% After Early Amtagvi Rollout Update - Has The Bull Case Changed?

Simply Wall St.
·
Aug 03

Iovance Biotherapeutics Schedules Second-quarter Results Conference Call

Reuters
·
Jul 30

Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026

GlobeNewswire
·
Jul 30

Iovance Biotherapeutics (IOVA) Rallies On Undervalued Claims, Is The Market Still Missing Fair Value?

Simply Wall St.
·
Jul 25

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Iovance Biotherapeutics (IOVA), Elevance Health (ELV) and InnovAge Holding (INNV)

TIPRANKS
·
Jul 20

Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 18

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 18

Does Reaffirmed 2026 Revenue Guidance And Cash Runway To 2028 Change The Bull Case For Iovance (IOVA)?

Simply Wall St.
·
Jul 05

Iovance Publishes Corporate Presentation on TIL Cell Therapy Platform, Amtagvi Launch and Pipeline Updates

Reuters
·
Jul 01

3 US Growth Stocks Analysts See Delivering Strong Earnings Through 2029

Simply Wall St.
·
Jun 25

Iovance Biotherapeutics (IOVA) Stock Could Be 53.2% Undervalued After New Shelf Filings

Simply Wall St.
·
Jun 23

Mizuho Securities Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA)

TIPRANKS
·
Jun 22